📣 VC round data is live. Check it out!

Meta Biomed Valuation Multiples

Discover revenue and EBITDA valuation multiples for Meta Biomed and similar public comparables like Cyclopharm, Senzime, FluoGuide, Optiscan Imaging and more.

Meta Biomed Overview

About Meta Biomed

Meta Biomed Co Ltd manufactures and markets suture and dental supplies. The company's dental products include endodontic materials, restorative materials, and bone graft material, as well as equipment, including Endo motor, and Endo System. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics and incontinence meshs; bone products consisting of bone substitutes and cement; and medical products, including endoscope and ultrasonic products.


Founded

1999

HQ

South Korea

Employees

N/A

Financials (FY)

Revenue: $70M
EBITDA: $14M

EV

$81M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Meta Biomed Financials

Meta Biomed reported last fiscal year revenue of $70M and EBITDA of $14M.

In the same fiscal year, Meta Biomed generated $37M in gross profit, $14M in EBITDA, and $8M in net income.


Meta Biomed P&L

In the most recent fiscal year, Meta Biomed reported revenue of $70M and EBITDA of $14M.

Meta Biomed is profitable as of last fiscal year, with gross margin of 52%, EBITDA margin of 20%, and net margin of 11%.

See analyst estimates for Meta Biomed
Last FY202320242025202620272028
Revenue$70M$57M$64M$70M
Gross Profit$37M$26M$32M$37M
Gross Margin52%46%50%52%
EBITDA$14M$10M$22M$14M
EBITDA Margin20%17%34%20%
EBIT Margin21%13%18%21%
Net Profit$8M$7M$15M$8M
Net Margin11%12%24%11%
Net Debt$16M

Financial data powered by Morningstar, Inc.

Meta Biomed Stock Performance

Meta Biomed has current market cap of $78M, and enterprise value of $81M.


Meta Biomed's stock price is $2.90.

Meta Biomed has an EPS (earnings per share) of $0.28.

See more trading valuation data for Meta Biomed
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$81M$78M-0.4%$0.28

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Meta Biomed Valuation Multiples

Meta Biomed trades at 1.1x EV/Revenue multiple, and 5.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Meta Biomed

Meta Biomed Financial Valuation Multiples

As of May 10, 2026, Meta Biomed has market cap of $78M and EV of $81M.

Meta Biomed has a P/E ratio of 10.3x.

Last FY202320242025202620272028
EV/Revenue1.1x1.4x1.3x1.1x
EV/EBITDA5.6x8.2x3.7x5.6x
EV/EBIT5.5x11.0x6.9x5.5x
EV/Gross Profit2.2x3.1x2.5x2.2x
P/E10.3x11.3x5.1x10.3x
EV/FCF(188.4x)(92.6x)10.3x(188.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Meta Biomed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Meta Biomed Margins & Growth Rates

In the most recent fiscal year, Meta Biomed reported gross margin of 52%, EBITDA margin of 20%, and net margin of 11%.

See estimated margins and future growth rates for Meta Biomed

Meta Biomed Margins

Last FY20242025202720282029
Gross Margin52%50%52%
EBITDA Margin20%34%20%
EBIT Margin21%18%21%
Net Margin11%24%11%
FCF Margin(1%)12%(1%)

Meta Biomed Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth13%9%
Gross Profit Growth25%13%
EBITDA Growth123%(35%)
EBIT Growth60%24%
Net Profit Growth122%(51%)
FCF Growth(1003%)(105%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Meta Biomed Operational KPIs

Access forward-looking KPIs for Meta Biomed
Last FY202320242025202620272028
S&M Expenses to Revenue6%6%6%6%
G&A Expenses to Revenue6%7%6%6%
R&D Expenses to Revenue5%5%5%5%
Opex to Revenue31%33%32%31%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Meta Biomed Competitors

Meta Biomed competitors include Cyclopharm, Senzime, FluoGuide, Optiscan Imaging, BioStem Technologies, Nexstim, Osang Healthcare, Medicalgorithmics, Applied BioCode and Sera Prognostics.

Most Meta Biomed public comparables operate across Medical Devices.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Cyclopharm3.4x3.2x(6.7x)(6.6x)
Senzime6.3x5.4x(6.6x)(8.2x)
FluoGuide(11.0x)(9.9x)
Optiscan Imaging98.1x(16.0x)
BioStem Technologies0.2x1.1x1.6x
Nexstim6.3x6.0x37.9x35.3x
Osang Healthcare0.9x10.5x
Medicalgorithmics11.6x7.4x(23.3x)2284.6x

This data is available for Pro users. Sign up to see all Meta Biomed competitors and their valuation data.

Start Free Trial

Meta Biomed Investment Activity

Meta Biomed has invested in 1 company to date.

Latest investment by Meta Biomed was on March 17th 2026. Meta Biomed invested in LabInCube in their $10M Series B round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Meta Biomed

LabInCube
LabInCube
Description
LabInCube is a Seoul-based developer of inCube hydrogel materials for controlled drug release in implants and wound dressings. Formulations enable sustained delivery of antibiotics and growth factors, supporting tissue regeneration in orthopedic and dental applications through partnerships with Korean hospitals.
LabInCube is a Seoul-based developer of inCube hydrogel materials for controlled drug release in implants and wound dressings. Formulations enable sustained delivery of antibiotics and growth factors, supporting tissue regeneration in orthopedic and dental applications through partnerships with Korean hospitals.
HQ CountrySouth KoreaSouth Korea
HQ City
Cheongju
Cheongju
Deal Date17 Mar 202630 Dec 2025
RoundSeries BStrategic investment
Raised$10Mundisclosed
InvestorsBNH Investment; JKP Partners; Meta Biomed; Union Investment PartnersMeta Biomed
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Meta Biomed investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Meta Biomed

When was Meta Biomed founded?Meta Biomed was founded in 1999.
Where is Meta Biomed headquartered?Meta Biomed is headquartered in South Korea.
Is Meta Biomed publicly listed?Yes, Meta Biomed is a public company listed on Korea Exchange.
What is the stock symbol of Meta Biomed?Meta Biomed trades under 059210 ticker.
When did Meta Biomed go public?Meta Biomed went public in 2008.
Who are competitors of Meta Biomed?Meta Biomed main competitors include Cyclopharm, Senzime, FluoGuide, Optiscan Imaging, BioStem Technologies, Nexstim, Osang Healthcare, Medicalgorithmics, Applied BioCode, Sera Prognostics.
What is the current market cap of Meta Biomed?Meta Biomed's current market cap is $78M.
What is the current revenue of Meta Biomed?Meta Biomed's last fiscal year revenue is $70M.
What is the current EV/Revenue multiple of Meta Biomed?Current revenue multiple of Meta Biomed is 1.1x.
Is Meta Biomed profitable?No, Meta Biomed is not profitable.
How many companies Meta Biomed has acquired to date?Meta Biomed hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Meta Biomed has invested to date?As of May 2026, Meta Biomed has invested in 1 company.
What was the last Meta Biomed investment?On 17th March 2026 Meta Biomed invested in LabInCube, participating in a $10M Series B round, alongside BNH Investment, JKP Partners, and Union Investment Partners.
In what companies Meta Biomed invested in?Meta Biomed invested in LabInCube.

See public comps similar to Meta Biomed

Lists including Meta Biomed

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial